NSCLC Therapeutics in Asia-Pacific Market 2019 - New Research Report Published By Radiant Insights

NSCLC Therapeutics in Asia-Pacific Market 2019 - New Research Report Published By Radiant Insights

  • Submitted By: vasu999
  • Date Submitted: 04/07/2015 5:03 AM
  • Category: Business
  • Words: 508
  • Page: 3
  • Views: 2

Summary

GBI Research, the leading business intelligence provider, has released its latest research, "NSCLC Therapeutics in Asia-Pacific Markets to 2019 - Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool", which provides in-depth insights into the Non-Small Cell Lung Cancer (NSCLC) indication. The report provides an estimation of the market size for 2012 along with market forecasts until 2019 for the Asia-Pacific (APAC) region, covering Australia, China, India and Japan. It also covers disease epidemiology, treatment algorithms, treatment patterns, clinical trial analysis (including failure rates), pipeline analysis, and analysis of deals relevant to NSCLC. The NSCLC market in the APAC region is estimated to have been worth $1.8 billion in 2012 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 6.3% to reach $2.9 billion by 2019.

Full Report Now Available For Radiant Insights Customer @ http://www.radiantinsights.com/research/nsclc-therapeutics-in-asia-pacific-markets-to-2019-personalized-therapies-focus-on-untapped-segment-of-squamous-cell-carcinoma-to-expand-treatment-pool

The key drivers for this growth include an aging population, an increasing number of NSCLC incident cases and the expected launch of promising therapies. The launch of premium-priced novel antibodies and immunotherapies in the first and second lines of therapy, including Boehringer Ingelheim's Gilotrif, Eli Lilly's necitumumab, Bristol-Myers Squibb's Yervoy (ipilimumab) and nivolumab, Pfizer's dacomitinib and Novartis's LDK378 are set to drive the market during the forecast period. However, the recent implementation of a price ceiling on essential drugs,dominance of generic drugs in India and expected pricing restrictions in China could curtail the NSCLC market in APAC countries.

Scope

The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and...

Similar Essays